ProCE Banner Activity

CE / CME

Assessing the Options for Advanced Renal Cell Carcinoma

PCE On Demand Live Presentation

In recent years there has been a shift in preferred first-line treatment options for advanced renal cell carcinoma (RCC), with emphasis now placed on combinations of targeted and immunotherapies, making treatment decisions and sequencing options for patients more complex. This activity provides expert advice on how to select preferred treatment regimens for individual patients with RCC, as well as manage treatment-related adverse events (AEs) to provide optimal care.

Registered Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit Physician Assistants: maximum of 1.00 hours of AAPA Category 1 CME credits

Released: September 29, 2022

Expiration: September 28, 2023

No longer available for credit.

Share

Faculty

Kathleen Madden

Kathleen Madden, MSN, ANP-BC, AOCNP

Melanoma Program
NYU Langone Perlmutter Cancer Center
New York, NY

Cristina Salabao

Cristina Salabao, MSN, FNP-C, AOCNP

Nurse Practitioner
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Acknowledgement

This activity is supported by an educational grant from: Merck Sharp & Dohme Corp.

Provided by

ProCE Banner

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify guideline-recommended first- and subsequent-line treatment options for advanced RCC

  • Differentiate AEs associated with VEGFR TKIs from those associated with immune checkpoint inhibitors (irAEs)

  • Utilize recommended monitoring and management strategies for AEs/irAEs in patients with RCC

Disclosure

All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Kathleen Madden, FNP, MSN, AOCNP, APHN: consultant/advisor/speaker: Novartis.

Cristina Salabao, MSN, FNP-C, AOCNP, has no relevant financial relationships to disclose.

None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose, except Kathleen Madden, FNP, MSN, AOCNP, APHN, as noted above.

Instructions for Credit

Participants wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete evaluation form

The estimated time to complete this activity is 1.00 hour.

Release date: September 29, 2022
Expiration date: September 28, 2023

Format

On-demand webcast

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Accreditation

PCE

Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until September 28, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credits for learning and change.

Additional Information

Program Medium

This program has been made available online.